ATCC provides a large collection of fully characterized and authenticated cell lines, human primary cells, and advanced cell models such as checkpoint luciferase reporter cells and CAR-T target luciferase reporter cells that support immuno-oncology therapeutic development.

Our newly developed animal by-product free McCoy’s 5A medium was tested across several ATCC cell lines for performance and was found to be a suitable substitute for the current McCoy’s 5A Medium.

This study showcases the development of a NIH/3T3 clonal derivative that maintains the contact inhibition property associated with this cell line.

To facilitate large-scale drug discovery of immune checkpoint inhibitors, ATCC created tumor and immune cell lines with high endogenous expression of checkpoint inhibitory and co-stimulatory expression levels.

ATCC generated CAR-T Target Luciferase Reporter Cells lines that have high endogenous expression of clinically relevant cell surface tumor antigens, such as CD19, CD20, and HER2. These new immuno-oncology tools are comprised of both solid and liquid tumor cell lines that exhibit sensitive and stable luciferase reporter expression.

Enjoy the best of all worlds with human telomerase reverse transcriptase (hTERT)-immortalized Primary Cells from ATCC.

This report describes ATCC luciferase reporter solid and liquid tumor cell lines that express tumor antigens such as CD19, CD20, and HER2. Learn how you can incorporate these target cells into your T-Cell cytotoxicity assays to enable your breakthroughs in immuno-oncology.

This guide organizes our ATCC tumor cell lines according to gene of interest and provides information for each line about the specific mutation.

A comprehensive guide providing details and data on our AKT, BRAF, EGFR, ERK, FGFR, MET, MYC, PI3K, PTEN, and RAS genetic alteration cell panels.

With genome editing tools such as CRISPR/Cas9, ATCC has created isogenic cell lines with mutants of key oncogenes, which are ideal for identifying novel, personalized treatment regimens. Explore our resources.

Tumor-derived cell lines matched to either normal or metastatic cell lines obtained from the same patient provide a valuable resource for cancer studies.

Using ATCC high-performance media, sera, and reagents will ensure robust, continuous cell growth, consistent performance, and minimum cell loss when reviving cells from cryopreservation.